Impact of tirofiban on serum troponin changes in patients undergoing carotid artery stenting: a propensity matched analysis
Background: The optional periprocedural antithrombotic management for carotid artery stenting (CAS) is still debated. Methods: We aimed to compare the procedural and 1-month outlook of patients undergoing CAS with tirofiban as parenteral antiplatelet therapy. We retrospectively compared patients receiving tirofiban during CAS versus those undergoing CAS without tirofiban, using propensity score matching. Ancillary antithrombotic therapy included in all patients aspirin, clopidogrel, and unfractioned heparin.